Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 2'-deoxyuridine 5'-alpha,beta-imido-diphosphate is a synthetic nucleotide analog belonging to the class of pyrimidine 2’-deoxyribonucleosides. It is structurally related to deoxyuridine diphosphate but features an imido (NH) linkage between the alpha and beta phosphate groups that renders it non-hydrolyzable by most enzymes. This property makes it valuable as a biochemical probe in studies of nucleotide metabolism and enzyme mechanisms involving nucleotides. The compound has been investigated for its potential applications in antiviral and anticancer therapy due to its ability to act as a stable substrate or inhibitor for enzymes such as dUTPase[1][3]. Its primary use remains experimental in research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-deoxyuridine 5'-alpha,beta-imido-diphosphate.